News | News By Subject | News by Disease News By Date | Search News

Renal Cell Carcinoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Exelixis (EXEL)' Cabozantinib Met Primary Endpoint in Phase II Renal Cell Carcinoma Study     5/23/2016
Exelixis (EXEL)'s Cabozantinib Shines in Late Stage Study for Patients with Advanced RCC     1/6/2016
AVEO Oncology (AVEO), EUSA Pharma Form $396.5 Million Exclusive Licensing Agreement for Tivozanib in Europe     12/21/2015
Bristol-Myers Squibb (BMY) Grabs Breakthrough Tag for Opdivo     9/16/2015
Revitalized Exelixis (EXEL) Grabs Breakthrough Tag for Cabozantinib     8/25/2015
Bristol-Myers Squibb (BMY)'s Opdivo Phase III Study Stopped Early on More Good Cancer Therapy News     7/21/2015
Embattled Exelixis (EXEL) Nabs Much-Needed Victory for Phase III Renal Cell Carcinoma Study     7/21/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test     3/19/2014
FDA Committee Turns Down AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO)/Astellas Pharma Inc. (YPH.BE)'s Cancer Drug     5/6/2013
Pfizer Inc. (PFE) Kidney Cancer Drug Fails as Initial Treatment     10/18/2012
Pfizer Inc. (PFE)'s Torisel Drug Fails in a Combination Study     8/13/2012
Pfizer Inc. (PFE)'s Torisel Fails Phase III Renal Cell Carcinoma Study in Showdown Against Bayer HealthCare (BAY)'s Nexavar     5/16/2012
Argos Therapeutics, Inc. Raises $25 Million Series D Financing     4/24/2012

News from Around the Web

Press Releases
Ipsen (IPN.PA)’s Partner Exelixis (EXEL) Announced Results From Randomized Phase 2 Trial CABOSUN That Demonstrate That Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma     5/24/2016
Rexahn Pharmaceuticals, Inc. (RNN) To Present At The ASCO 2016 Annual Meeting     5/23/2016
FDA Approves Eisai Inc. (ESALF.PK)'s LENVIMA (Lenvatinib) For The Treatment Of Patients With Advanced Renal Cell Carcinoma In Combination With Everolimus Following Prior Anti-Angiogenic Therapy     5/16/2016
Mirna Reports First Quarter 2016 Financial Results And Program Updates     5/13/2016
AVEO Oncology (AVEO) Reports First Quarter 2016 Financial Results And Provides Business Update     5/11/2016
X4 Pharma Announces Initiation Of Phase 1/2 Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma     5/9/2016
Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results     5/5/2016
Exelixis (EXEL)-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting     4/20/2016
Cerulean Pharma Inc. (CERU) Announces Presentation At 2016 AACR Annual Meeting Of Stage 1 Data From Phase 2 Trial In Platinum-Resistant Ovarian Cancer     4/19/2016
Arrowhead Pharma (ARWR) Presents Preclinical Data On Renal Cell Carcinoma Program At AACR 2016     4/19/2016
European Commission (EC) Approves Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) For Previously Treated Advanced Renal Cell Carcinoma     4/6/2016
Merck & Co. (MRK) And Pfizer (PFE) Announce First Patient Treated In Phase III Combination Study With Avelumab And INLYTA In Renal Cell Carcinoma     4/5/2016
AVEO Oncology (AVEO) Reports Full Year 2015 Financial Results And Provides Business Update     3/15/2016
Cerulean Pharma Inc. (CERU) Reports Fourth Quarter 2015 Corporate Highlights And Financial Results     3/11/2016
EUSA Pharma And AVEO Oncology (AVEO) Announce Submission Of Marketing Authorization Application For Tivozanib In Advanced Renal Cell Carcinoma     3/1/2016

//-->